Cardiotoxicity After the Lymphoma

Creative Commons License

ÖZEN A., Fayda M.

Turk Onkoloji Dergisi, vol.37, no.2, pp.44-50, 2022 (ESCI) identifier

  • Publication Type: Article / Review
  • Volume: 37 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.5505/tjo.2022.s1007
  • Journal Name: Turk Onkoloji Dergisi
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.44-50
  • Keywords: Cardiotoxicity, Hodgkin Lymphoma (HL), radiotherapy
  • Eskisehir Osmangazi University Affiliated: Yes


© 2022.SUMMARY Radiotherapy (RT) is the cornerstone component of the current successful treatment of Hodgkin lymphoma (HL). Although RT has been used alone to cure in most patients in decades, combined modality regimes are preferred in most HL patients currently, besides early-stage lymphocyte predominance HL and for selected patients with classical HL who have contraindications to chemotherapy. Although clas-sic RT fields, doses, and techniques have fundamentally changed over the years, the heart is still an organ at risk, and patients with radiation-induced cardiovascular complications are increased in the long term. In this paper, we aimed to review literature about radiation-induced cardiotoxicity in lymphoma patients treated with mediastinal RT.